Homocysteine and vascular disease

Area of Science:

• Cardiovascular Research
• Vascular Biology
• Biomarkers

Background:

• Moderately raised total homocysteine concentrations have been associated with increased atherothrombotic vascular risk for over two decades.
• Recent evidence suggests this association may be causal, supported by consistency, strength, dose-dependency, and biological plausibility.

Purpose of the Study:

• To evaluate the causal link between elevated total homocysteine and atherothrombotic vascular events.
• To assess the potential of lowering homocysteine as a therapeutic strategy for vascular risk reduction.

Main Methods:

• Review of existing studies on total homocysteine and vascular events.
• Emphasis on the need for systematic reviews and randomized controlled trials (RCTs).
• Highlighting the requirement for standardized total homocysteine measurement.

Main Results:

• The association between total homocysteine and vascular risk is independent of other factors and biologically plausible.
• Evidence suggests a strong, dose-related correlation across numerous studies.
• RCTs are crucial to demonstrate that reducing homocysteine levels leads to a significant decrease in atherothrombotic events.

Conclusions:

• Further research, including systematic reviews and RCTs, is necessary to solidify the causal relationship.
• Standardization of homocysteine measurement is essential for clinical utility.
• Successful interventions could establish homocysteine as a key vascular risk marker and support multivitamin therapy and folic acid fortification.